Enliven Therapeutics director proposes $9.22M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Enliven Therapeutics, Inc. director Mika K. Derynck reported a proposed sale of 158,795 common shares, with an aggregate market value of $9,216,461.80. The notice gives an approximate sale date of August 4, 2026 and states that the sales are to be made under a previously signed/adopted Rule 10b5-1 Selling Plan dated April 8, 2025. The notice lists 71,000,000 common shares outstanding.
Key Figures
Key Terms
10b5-1 Selling Plan regulatory
Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.